Stock VTGN VISTAGEN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Chart Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-17 pm EDT 		5-day change 1st Jan Change
4.44 USD -2.42% Intraday chart for Vistagen Therapeutics, Inc. +1.60% -13.62%
Apr. 25 Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue CI
Apr. 01 Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 CI
d157a038c0ef1646ae1ad75f543dda.vYL6r8ntvEI7_RIJckbnM4RIijkZt9g6EhVofxMlGa0.6O3NzbO7jgsL0FFoCgeUWOAM4nRG1LBVeXEJCWltYf6E0Yj9oaDJG3mxeQ~a941a10a745d037b94f0c76f317affbb
  1. Stock Market
  2. Equities
  3. VTGN Stock
  4. Charts Vistagen Therapeutics, Inc.
  5. News Chart
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW